VistaGen to Participate in Upcoming June Investor Conferences

Rhea-AI Summary

VistaGen Therapeutics (Nasdaq: VTGN) announced participation in two upcoming investor conferences in June: the William Blair 42nd Annual Growth Stock Conference on June 7 at 2:00 PM CT in Chicago, and the Jefferies Global Healthcare Conference on June 9 at 10:00 AM ET in New York. CEO Shawn Singh will engage in discussions aimed at transforming treatment for anxiety and depression. The company’s lead candidate, PH94B, is positioned to be a leading fast-acting treatment for social anxiety disorder, currently undergoing Phase 3 trials in the U.S.

VistaGen will present at upcoming William Blair 42^nd Annual Growth Stock Conference and Jefferies Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders, today announced that Shawn Singh, Chief Executive Officer, will participate in the following upcoming investor conferences in June. Management will be available for one-on-one meetings during these conferences.

William Blair 42^nd Annual Growth Stock Conference
Format: Fireside Chat
Date and Time: Tuesday, June 7^th at 2:00pm Central Time
Location: Chicago, IL

Jefferies Global Healthcare Conference
Format: Company Presentation
Date and Time: Thursday, June 9^th at 10:00am Eastern Time
Location: New York, NY

The live and archived webcasts of VistaGen’s fireside chat and presentation will be accessible through the News/Events page of the Investors section of the Company’s website at www.VistaGen.com.

About VistaGen
VistaGen (Nasdaq: VTGN) is a late clinical-stage, CNS-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The Company is advancing first-in-class therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are currently available. VistaGen’s clinical-stage candidates are targeting multiple forms of anxiety and depression. They belong to a new class of drugs known as pherines, which are odorless, neuroactive steroids that bind to distinct receptors on chemosensory neurons in the nasal passages and can impact the olfactory to limbic amygdala circuit without systemic uptake or direct activity on CNS neurons in the brain. VistaGen’s lead candidate, PH94B, is a nasally administered spray currently in multiple Phase 3 trials in the U.S., with results anticipated in 2022. Should ongoing Phase 3 studies be successful, PH94B has the potential to be the first FDA-approved, fast-acting, acute treatment of anxiety for adults with social anxiety disorder. With an experienced leadership team and a steady flow of near- and long-term potential milestones, VistaGen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety and depression. Connect at www.VistaGen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220527005062/en/

Investors

Mark Flather

Vice President, Investor Relations, VistaGen Therapeutics

Phone: (650) 577-3617

Email: mflather@vistagen.com



Media

Nate Hitchings

SKDK

Email: nhitchings@skdknick.com

Source: VistaGen Therapeutics, Inc.

FAQ

What are the dates and locations of the upcoming conferences for VistaGen (VTGN)?

VistaGen Therapeutics will participate in the William Blair 42nd Annual Growth Stock Conference on June 7 in Chicago and the Jefferies Global Healthcare Conference on June 9 in New York.

Who will represent VistaGen (VTGN) at the investor conferences?

CEO Shawn Singh will represent VistaGen Therapeutics at the upcoming investor conferences.

What is VistaGen's lead candidate, and what is its significance?

VistaGen's lead candidate, PH94B, is a nasally administered spray targeting social anxiety disorder and is anticipated to be the first FDA-approved fast-acting treatment for this condition.

When will the results from VistaGen's Phase 3 trials for PH94B be available?

Results from VistaGen’s Phase 3 trials for PH94B are expected in 2022.

How can investors access the webcasts of VistaGen's conference presentations?

Webcasts of VistaGen's presentations will be accessible on the News/Events page of the Investors section on their website.